Development of the “Inje Cocktail” for High‐throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo
作者： J Y Ryu , I S Song , Y E Sunwoo , J H Shon , K H Liu
关键词:
摘要: To develop and validate an in vivo cocktail method for high-throughput phenotyping of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, 12 healthy subjects received five probe drugs alone or simultaneously. The index the ratio 8 h urine concentration losartan to its metabolite after a single administration losartan, was not significantly different from that obtained using five-drug cocktail. Similarly, ratios [omeprazole]/[5-hydroxyomeprazole] (CYP2C19) [paraxanthine]/[caffeine] (CYP1A2) 4 plasma samples log [dextromethorphan]/[dextrorphan] (CYP2D6) concentrations midazolam (CYP3A) well-established three-drug caffeine, omeprazole, dextromethorphan were those new In conclusion, regimen, named "Inje cocktail," can be used as tool phenotype enzyme activities CYP3A with only blood sampling collection following simultaneous drugs.
nature.com
sci-hub.se 参考文章(47)
Line Labbe, Caroline Sirois, Sylvie Pilote, Marie Arseneault, N. Robitaille, Jacques Turgeon, Bettina Hamelin, Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates Pharmacogenetics. ,vol. 10, pp. 425- 438 ,(2000) , 10.1097/00008571-200007000-00006
J. L. Palmer, R. J. Scott, A. Gibson, M. Dickins, S. Pleasance, An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). British Journal of Clinical Pharmacology. ,vol. 52, pp. 555- 561 ,(2001) , 10.1046/J.0306-5251.2001.01479.X
G. E. Blakey, J. A. Lockton, J. Perrett, P. Norwood, M. Russell, Z. Aherne, J. Plume, Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1 British Journal of Clinical Pharmacology. ,vol. 57, pp. 162- 169 ,(2003) , 10.1046/J.1365-2125.2003.01973.X
Mats Hidestrand, Magnus Ingelman-Sundberg, Ümit Yasar, Gunnel Tybring, Marja-Liisa Dahl, Mikael Oscarson, Erik Eliasson, Role of CYP2C9 Polymorphism in Losartan Oxidation Drug Metabolism and Disposition. ,vol. 29, pp. 1051- 1056 ,(2001)
L Gonzales, JA Lopez, RM Alonso, RM Jimenez, None, Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. Journal of Chromatography A. ,vol. 949, pp. 49- 60 ,(2002) , 10.1016/S0021-9673(01)01496-0
HJ Gill, MD Tingle, BK Park, N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450 : implications for inhibition of haemotoxicity British Journal of Clinical Pharmacology. ,vol. 40, pp. 531- 538 ,(1995) , 10.1111/J.1365-2125.1995.TB05797.X
Jang‐Ik Lee, Diego Chaves‐Gnecco, Janet A Amico, Patricia D Kroboth, John W Wilson, Reginald F Frye, Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clinical Pharmacology & Therapeutics. ,vol. 72, pp. 718- 728 ,(2002) , 10.1067/MCP.2002.129068
Daniel S. Streetman, Joseph S. Bertino, Anne N. Nafziger, Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. ,vol. 10, pp. 187- 216 ,(2000) , 10.1097/00008571-200004000-00001
J. Christopher Gorski, David R. Jones, Barbara D. Haehner-Daniels, Mitchell A. Hamman, Edward M. O'Mara, Stephen D. Hall, The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology & Therapeutics. ,vol. 64, pp. 133- 143 ,(1998) , 10.1016/S0009-9236(98)90146-1
A Rostami-Hodjegan, S Nurminen, P R Jackson, G T Tucker, Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics. ,vol. 6, pp. 121- 149 ,(1996) , 10.1097/00008571-199604000-00001